All In Biotech

Drug Trial Radar · NCT05276063

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

90

Actual

Start

Jul 1, 2022

Primary completion

Oct 15, 2024

Study completion Sep 26, 2025

Sponsor

Lead sponsor
Sling Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).

Conditions

  • Thyroid Eye Disease
  • Graves Orbitopathy
  • Endocrine System Diseases
  • Eye Diseases
  • Thyroid Associated Ophthalmopathy
  • Graves Ophthalmopathy
  • Thyroid Diseases
  • Orbital Diseases
  • Proptosis
  • IGF1R
  • Exophthalmos
  • Hashimoto

Interventions

  • LinsitinibDrug

    Study medication taken twice daily by mouth

  • PlaceboDrug

    Placebo taken twice daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Who Are Proptosis Responders at Week 24Time frame: 24 weeks

Locations

30 sites in 5 countries. Site status is shown where the registry gives one.

  • Thrive Health Research

    Beverly Hills, California

  • UC San Diego Health

    La Jolla, California

  • UCLA

    Los Angeles, California

  • Byers Eye Institute - Stanford University

    Palo Alto, California

  • Bascom Palmer Eye Institute

    Miami, Florida

  • Center for Excellence in Eye Care

    Miami, Florida

  • Sarasota Retina Institute

    Sarasota, Florida

  • Chicago Oculofacial Plastic Surgery

    Chicago, Illinois

  • Wolfe Eye Clinic

    West Des Moines, Iowa

  • Mass Eye and Ear

    Boston, Massachusetts

  • Kellogg Eye Center

    Ann Arbor, Michigan

  • Kahana Oculoplastic & Orbital Surgery

    Livonia, Michigan

  • Washington University in St. Louis/Barnes Jewish Hospital

    Creve Coeur, Missouri

  • Columbia University

    New York, New York

  • Wake Forest Baptist Health Eye Center

    Winston-Salem, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Neuro-Eye Clinical Trials, Inc.

    Bellaire, Texas

  • Eyelid Center of Utah

    Salt Lake City, Utah

  • West Virginia University Eye Institute

    Morgantown, West Virginia

  • Toronto Retina Institute

    North York, Canada

  • Vancouver Coastal Health Eye Care Center

    Vancouver, British Columbia, Canada

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Endocrinology Pawilione Zonda

    Milan, Italy

  • AOU Pisana

    Pisa, Italy

  • University of Pisa

    Pisa, Italy

  • Hospital Universitari de Bellvitge

    Barcelona, Spain

  • Hospital La Princesa

    Madrid, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Frimley Health Foundation Trust

    Camberley, United Kingdom

  • Cardiff University

    Cardiff, United Kingdom

  • Moorfields Eye Hospital NIHR Clinical Research Facility

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.